
PROPOSED PLACEMENT OF 562,500,000 NEW ORDINARY SHARES IN THE SHARE CAPITAL OF OUE LIPPO HEALTHCARE LIMITED AT THE ISSUE PRICE OF S\$0.14 FOR EACH NEW SHARE

- **COMPLETION OF THE PLACEMENT OF THE PLACEMENT SHARES**
 - **APPOINTMENT OF DIRECTORS**
-

1. INTRODUCTION

The Board of Directors of OUE Lippo Healthcare Limited (the “**Company**”, and together with its subsidiaries the “**Group**”) (the “**Board**”) refers to (a) the announcement of the Company dated 10 January 2018 in relation to the issuance of 562,500,000 new ordinary shares in the share capital of the Company pursuant to a placement agreement entered into with Brownly Healthcare Pte Ltd (the “**Subscriber**”); and (b) the announcement dated 12 February 2018 in relation to the receipt of the listing and quotation notice (“**LQN**”) from the SGX-ST for the listing and quotation of the Placement Shares on the Catalist Board (collectively, the “**Earlier Announcements**”).

Capitalised terms used herein shall have the definitions ascribed to them in the Earlier Announcements, unless otherwise stated or the context otherwise requires.

2. COMPLETION OF PLACEMENT

Further to the Earlier Announcements, the Board is pleased to announce that the Company has, on 15 February 2018, completed the allotment and issuance of 562,500,000 Placement Shares to the Subscriber.

Following Completion:

- (a) the total issued share capital of the Company increased from 1,659,064,603 Shares to 2,221,564,603 Shares, being the enlarged issued and paid-up share capital after the issue and allotment of the Placement Shares; and
- (b) the Placement Shares rank *pari passu* and carry all rights similar to the existing Shares.

The LQN is not to be taken as an indication of the merits of the Placement, the Placement Shares, the Group and their securities.

3. APPOINTMENT OF DIRECTORS

Approval for Appointment of New Directors

In connection with the Placement, the Board is pleased to announce that it has approved the appointment of the following persons as directors of the Company:

- (a) Mr. Masato Mohri as Non-Independent and Non-Executive Director; and

(b) Mr. Johji Sato as Independent Director.

Mr. Johji Sato's appointment takes effect from 15 February 2018 while Mr. Masato Mohri's appointment remains subject to consent from the Ministry of Manpower and will only take effect after such consent has been received.

Details of the appointment of Mr. Johji Sato is contained in the separate announcement released today as required under Rule 704(6) of the Catalist Rules.

Following the appointment of Mr. Johji Sato and Mr. Masato Mohri, the Board will be constituted as follows:

- Mr. Lee Yi Shyan (*Non-Independent and Non-Executive Chairman*)
- Dr Stephen Riady (*Non-Independent and Non-Executive Director*)
- Dr Wong Weng Hong (*Chief Executive Officer and Executive Director*)
- Mr. Masato Mohri (*Non-Independent and Non-Executive Director*)
- Mr. Roger Tan Chade Phang (*Lead Independent Director*)
- Mr. Eric Sho Kian Hin (*Independent Director*)
- Mr. Jackson Tay Eng Kiat (*Independent Director*)
- Mr. Johji Sato (*Independent Director*)

Appointment to Audit and Risk Committee

With effect from 15 February 2018, Mr. Johji Sato has been appointed to the Audit and Risk Committee of the Company. The Board considers Mr. Johji Sato as an independent Director of the Company in accordance with Rule 704(7) of the Catalist Rules.

In consequence thereof, the composition of the Company's Audit and Risk Committee with effect from 15 February 2018 will be as follows:

- Mr. Eric Sho Kian Hin (Chairman)
- Mr. Roger Tan Chade Phang (Member)
- Mr. Jackson Tay Eng Kiat (Member)
- Mr. Johji Sato (Member)

By Order of the Board,

OUE Lippo Healthcare Limited

Dr. Wong Weng Hong

Chief Executive Officer and Executive Director

19 February 2018

*This announcement has been prepared by OUE Lippo Healthcare Limited (formerly known as International Healthway Corporation Limited) (the “**Company**”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809 **T:** +65 6578 9188 **F:** 64794647

www.ouelh.com